{"ticker": {"uuid": "784d49ee-c7d0-4f4d-88ea-6bb66bbfce56", "symbol": "NRXP", "name": "NRX Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Is NRx Pharmaceuticals, Inc. (NRXP) Stock Positioned for Growth Through Depression and PTSD Treatment Innovation?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPaU5kMUt0QWhmM3I1azVFWVhCbVNOZEVqbXotTHdlblJteFlxcmlkcmxHVHp2clZzdVA2SldNVzZhbklWdmVWcmV0UzVLTWRQc1Y4aXZldDJRM2tCbjJmVFFHN19WTTRTSTFnQWl3SGgxeEh0eGtMclpoTFRkbDZhZVZnMllSR1lRTklseVhvTlg0Yi1LdEtnMlMzRQ?oc=5", "source_name": "Market source", "published_at": "2026-07-15T09:21:51+00:00", "published_display": "15 Jul 2026 09:21", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Equity in earnings of NRX Pharmaceuticals, Inc. \u2013 DUS:B1Q", "summary": "This article provides financial information for NRX Pharmaceuticals, Inc. (DUS:B1Q) as listed on the Dusseldorf Stock Exchange. It specifically highlights the \"Equity in earnings\" for the company. The content appears to be a stub or a section from a larger financial data platform", "url": "https://www.tradingview.com/symbols/DUS-B1Q/financials-income-statement/equity-in-earnings/", "source_name": "TradingView", "published_at": "2026-07-09T06:12:07", "published_display": "09 Jul 2026 06:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRX Pharmaceuticals(NRXP) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAJBVV95cUxOTVlwU2p5UUpwd2cxZFh0TGhES3ZFcTd1V3hIXzk1OE9ERXBQWnVDaWVjMFZEcGx6aUxpdjJ2eHlWYno0WW9GajBXY2xQT0ZReUFIbUx4RUVmYk4wSHpVWk5ucWVDU2I2eXBJYTRxWjA0THhudUxCUkdzWWZoeXVPOVVHTEFpNER3bFBvdWdRbXNOODBqVGxpVGRzS0xEQ0tNXzNqUnUyeTFVdXBKOHN5TFZLVE5BbDY0MnhLd3NicTIwLVF5UGdiVURoN0NiY0NMd2lLYTRoOFVYNHRRdGZJYXEtampZWnU4bC03RG1FWEVGeDhZczNiRWVCVWxxWnVvaFNFZTNOVWVoSXBjVVBXQmpBazB6Tmdqd0tHSjQtOVpWVHJQbWVxajZHYTE?oc=5", "source_name": "Moomoo", "published_at": "2026-07-08T02:57:12+00:00", "published_display": "08 Jul 2026 02:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of NRX Pharmaceuticals, Inc. \u2013 NASDAQ:NRXP", "summary": "The article focuses on the enterprise value to revenue forward metric for NRX Pharmaceuticals, Inc. (NASDAQ: NRXP). It appears to be a financial data snippet from TradingView, indicating no current trades and providing an overview of where to find financial and market information", "url": "https://www.tradingview.com/symbols/NASDAQ-NRXP/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T11:09:16", "published_display": "04 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "First Patients Treated via FDA-Cleared Transcranial Magnetic Stimulation, Plus FDA Grant on D-Cycloserine-Based Drug for Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)", "summary": "NRx Pharmaceuticals, Inc. (NRXP) announced that its subsidiary, HOPE Therapeutics, has begun treating patients with the FDA-cleared Zeta TMS Navigation System for depression. Additionally, the FDA granted an Intermediate Population Expanded Access Protocol for NRX-101 (D-cycloser", "url": "https://www.barchart.com/story/news/3032983/first-patients-treated-via-fdacleared-transcranial-magnetic-stimulation-plus-fda-grant-on-dcycloserinebased-drug-for-depression-nrx-pharmaceuticals-inc-nasdaq-nrxp", "source_name": "Barchart.com", "published_at": "2026-06-30T04:40:21", "published_display": "30 Jun 2026 04:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals, Inc.(NasdaqCM:NRXP) dropped from Russell 3000E Growth Benchmark", "summary": "NRx Pharmaceuticals, Inc. (NasdaqCM: NRXP) has been removed from the Russell 3000E Growth Benchmark. The clinical-stage biopharmaceutical company focuses on developing therapeutics for central nervous system disorders, including suicidal depression, chronic pain, and PTSD. The ar", "url": "https://www.marketscreener.com/news/nrx-pharmaceuticals-inc-nasdaqcm-nrxp-dropped-from-russell-3000e-growth-benchmark-ce7f5fdeda81f42d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:41:44", "published_display": "29 Jun 2026 05:41", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals, Inc.(NasdaqCM:NRXP) dropped from Russell Microcap Growth Benchmark Index", "summary": "NRx Pharmaceuticals, Inc. (NasdaqCM:NRXP) has been removed from the Russell Microcap Growth Benchmark Index. This follows a previous announcement on June 29th that the company was also dropped from the Russell 3000E Growth Benchmark. NRx Pharmaceuticals is a clinical-stage biopha", "url": "https://www.marketscreener.com/news/nrx-pharmaceuticals-inc-nasdaqcm-nrxp-dropped-from-russell-microcap-growth-benchmark-index-ce7f5fdcd88fff23", "source_name": "marketscreener.com", "published_at": "2026-06-29T03:39:09", "published_display": "29 Jun 2026 03:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of NRX Pharmaceuticals, Inc. \u2013 DUS:B1Q", "summary": "The article focuses on the enterprise value to revenue forward metric for NRX Pharmaceuticals, Inc. (DUS:B1Q), traded on the Dusseldorf Stock Exchange. It highlights financial data and market information related to the company's valuation. The content appears to be a stub or a se", "url": "https://www.tradingview.com/symbols/DUS-B1Q/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T16:10:38", "published_display": "28 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition", "summary": "Kadima Neuropsychiatry Institute and its founder, Dr. David Feifel, have filed a lawsuit against NRx Pharmaceuticals (NASDAQ: NRXP) and its subsidiaries, alleging breach of contract and misrepresentation regarding an acquisition agreement. The suit claims NRx warranted it had suf", "url": "https://finance.yahoo.com/markets/stocks/articles/kadima-neuropsychiatry-institute-files-suit-171800479.html", "source_name": "Market source", "published_at": "2026-06-28T05:09:48", "published_display": "28 Jun 2026 05:09", "sentiment": "negative", "sentiment_pct": 14, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of NRX Pharmaceuticals, Inc. \u2013 DUS:B1Q", "summary": "The article displays the \"Price to book forward\" for NRX Pharmaceuticals, Inc. (DUS:B1Q) on the Dusseldorf Stock Exchange according to TradingView. It indicates that the market is currently closed with no trades. The core content is limited to this financial metric and general ma", "url": "https://www.tradingview.com/symbols/DUS-B1Q/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T00:10:17", "published_display": "28 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of NRX Pharmaceuticals, Inc. \u2013 NASDAQ:NRXP", "summary": "This article provides a brief snapshot of the \"Price to sales forward\" metric for NRX Pharmaceuticals, Inc. (NASDAQ: NRXP) as listed on TradingView. It indicates that no specific value or change information is currently displayed, suggesting the data may be unavailable or pending", "url": "https://www.tradingview.com/symbols/NASDAQ-NRXP/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T00:10:17", "published_display": "28 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of NRX Pharmaceuticals, Inc. \u2013 DUS:B1Q", "summary": "This article provides financial information for NRX Pharmaceuticals, Inc. (B1Q) on the Dusseldorf Stock Exchange. It specifically highlights the \"Price to sales forward\" metric for the company. The content appears to be a stub or a data point from a financial platform, indicating", "url": "https://www.tradingview.com/symbols/DUS-B1Q/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T23:39:10", "published_display": "27 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System", "summary": "NRx Pharmaceuticals' subsidiary, HOPE Therapeutics, has started treating patients using Zeta Surgical's FDA-cleared Zeta TMS Navigation System at its clinics in Florida. This system employs AI-powered, sub-millimetric image guidance for Transcranial Magnetic Stimulation (TMS) pro", "url": "https://finance.yahoo.com/healthcare/articles/nrx-pharmaceuticals-nasdaq-nrxp-subsidiary-110000556.html", "source_name": "Market source", "published_at": "2026-06-27T19:10:06", "published_display": "27 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression", "summary": "NRx Pharmaceuticals announced that the FDA has granted an Intermediate Population Expanded Access Protocol for NRX-101, a D-cycloserine-based drug, to augment Transcranial Magnetic Stimulation (TMS) in patients with treatment-resistant depression. This protocol allows access to N", "url": "https://finance.yahoo.com/healthcare/articles/nrx-pharmaceuticals-announces-fda-grant-110000219.html", "source_name": "Market source", "published_at": "2026-06-26T16:39:35", "published_display": "26 Jun 2026 16:39", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Keeps Their Buy Rating on NRX Pharmaceuticals (NRXP)", "summary": "H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on NRX Pharmaceuticals (NRXP) with a $45.00 price target, highlighting his strong track record in the Healthcare sector. The analyst consensus for NRX Pharmaceuticals remains a Strong Buy with an average price targe", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/16051/h-c-wainwright-keeps-their-buy-rating-on-nrx-pharmaceuticals-nrxp/", "source_name": "The Globe and Mail", "published_at": "2026-06-26T12:49:31", "published_display": "26 Jun 2026 12:49", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRX Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:NRXP)", "summary": "This article provides an overview of NRX Pharmaceuticals, Inc. (NASDAQ: NRXP) stock performance, financial actuals, and analyst estimates. It covers the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings reports, along with an", "url": "https://www.tradingview.com/symbols/NASDAQ-NRXP/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T04:39:23", "published_display": "26 Jun 2026 04:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute", "summary": "NRx Pharmaceuticals (NRXP) issued a statement addressing \"unfounded allegations\" made by Kadima Neuropsychiatry Institute concerning the non-acquisition of Kadima by HOPE Therapeutics, an NRx subsidiary. NRx stated that it has compelled arbitration due to Kadima's failure to meet", "url": "https://www.globenewswire.com/news-release/2026/06/25/3317921/0/en/nrx-pharmaceuticals-responds-to-recent-public-statements-regarding-kadima-dispute.html", "source_name": "GlobeNewswire", "published_at": "2026-06-25T20:09:57", "published_display": "25 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System", "summary": "HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, has begun treating patients using Zeta Surgical's FDA-cleared Zeta TMS Navigation System at its clinics in West Palm Beach and Sarasota, Florida. This marks the transition from research deployment to active patient care, inc", "url": "https://investingnews.com/nrx-pharmaceuticals-subsidiary-hope-therapeutics-treats-first-patients-using-zeta-surgical-s-fda-cleared-zeta-tms-navigation-system/", "source_name": "Investing News Network", "published_at": "2026-06-25T14:09:57", "published_display": "25 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HOPE starts first FDA-cleared TMS treatments in Florida clinics", "summary": "NRx Pharmaceuticals' subsidiary, HOPE Therapeutics, has begun treating patients with Zeta Surgical's FDA-cleared Zeta TMS Navigation System in West Palm Beach and Sarasota, Florida. This system provides AI-guided, sub-millimetric image guidance for Transcranial Magnetic Stimulati", "url": "https://www.stocktitan.net/news/NRXP/n-rx-pharmaceuticals-nasdaq-nrxp-subsidiary-hope-therapeutics-treats-imxuappq0nn1.html", "source_name": "Stock Titan", "published_at": "2026-06-25T10:41:06", "published_display": "25 Jun 2026 10:41", "sentiment": "positive", "sentiment_pct": 76, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kadima Neuropsychiatry Institute Sues NRX Pharmaceuticals Over Breach of Acquisition Contract", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/kadima-neuropsychiatry-institute-sues-nrx-184440397.html", "source_name": "MT Newswires", "published_at": "2026-06-24T18:44:40+00:00", "published_display": "24 Jun 2026 18:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kadima sues NRx Pharmaceuticals over failed acquisition deal", "summary": "Kadima Neuropsychiatry Institute has filed a lawsuit against NRx Pharmaceuticals and its subsidiaries, alleging breach of contract and misrepresentation regarding a failed acquisition deal. Kadima claims NRx announced the acquisition and saw a significant stock surge, but then in", "url": "https://m.uk.investing.com/news/stock-market-news/kadima-sues-nrx-pharmaceuticals-over-failed-acquisition-deal-93CH-4742937?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-24T18:39:42", "published_display": "24 Jun 2026 18:39", "sentiment": "negative", "sentiment_pct": 13, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EBIT per share of NRX Pharmaceuticals, Inc. \u2013 DUS:B1Q", "summary": "The article provides the EBIT (Earnings Before Interest and Taxes) per share for NRX Pharmaceuticals, Inc., traded on the Dusseldorf Stock Exchange under the symbol B1Q. It indicates that the market is closed with no recent trades. The content is presented as a financial data poi", "url": "https://www.tradingview.com/symbols/DUS-B1Q/financials-statistics-and-ratios/ebit-per-share/", "source_name": "TradingView", "published_at": "2026-06-24T13:39:49", "published_display": "24 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cash per share of NRX Pharmaceuticals, Inc. \u2013 DUS:B1Q", "summary": "The article focuses on the \"Cash per share\" financial metric for NRX Pharmaceuticals, Inc. (DUS:B1Q) listed on the Dusseldorf Stock Exchange. It appears to be a financial data page from TradingView, indicating the company's financial overview, specifically its cash per share valu", "url": "https://www.tradingview.com/symbols/DUS-B1Q/financials-statistics-and-ratios/cash-per-share/", "source_name": "TradingView", "published_at": "2026-06-24T13:10:31", "published_display": "24 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tangible book value per share of NRX Pharmaceuticals, Inc. \u2013 DUS:B1Q", "summary": "This article provides financial data for NRX Pharmaceuticals, Inc. (DUS:B1Q) from TradingView, specifically focusing on its tangible book value per share. The content indicates the market status as closed with no recent trades for the stock on the Dusseldorf Stock Exchange. It hi", "url": "https://www.tradingview.com/symbols/DUS-B1Q/financials-statistics-and-ratios/book-tangible-per-share/", "source_name": "TradingView", "published_at": "2026-06-23T22:12:51", "published_display": "23 Jun 2026 22:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRX Pharmaceuticals' Hope Therapeutics, Zeta Surgical Treat First Patient With Zeta TMS Navigation System", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/nrx-pharmaceuticals-apos-hope-therapeutics-162121693.html", "source_name": "MT Newswires", "published_at": "2026-06-23T16:21:21+00:00", "published_display": "23 Jun 2026 16:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals gets FDA approval for NRX-101 protocol", "summary": "NRx Pharmaceuticals (NASDAQ:NRXP) has received FDA authorization for an expanded access program for its depression treatment drug candidate, NRX-101. This compassionate care decision allows the medication to be obtained by physicians with patients only covering shipping and data ", "url": "https://grafa.com/en/news/united-states/nrx-pharmaceuticals-nrxp-fda-approval-nrx-101-depression-2026", "source_name": "grafa.com", "published_at": "2026-06-22T13:46:00", "published_display": "22 Jun 2026 13:46", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals Receives Expanded Access Approval for Experimental Depression Treatment", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/nrx-pharmaceuticals-receives-expanded-access-115612841.html", "source_name": "MT Newswires", "published_at": "2026-06-22T11:56:12+00:00", "published_display": "22 Jun 2026 11:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals Announces FDA Grant of Expanded Access", "summary": "NRx Pharmaceuticals announced that the FDA has granted an Intermediate Population Expanded Access Protocol for NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. This protocol allows the investigational drug to be used in conjunction with Transcranial Magnet", "url": "https://www.globenewswire.com/news-release/2026/06/22/3315163/0/en/nrx-pharmaceuticals-announces-fda-grant-of-expanded-access-protocol-for-use-of-d-cycloserine-based-nrx-101-for-augmentation-of-transcranial-magnetic-stimulation-in-the-treatment-of.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T11:00:28", "published_display": "22 Jun 2026 11:00", "sentiment": "positive", "sentiment_pct": 94, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA lets NRx offer NRX-101 with TMS for severe depression", "summary": "NRx Pharmaceuticals announced that the FDA has authorized an Intermediate Population Expanded Access Protocol for NRX-101 to be used with accelerated Transcranial Magnetic Stimulation (TMS) for Treatment-Resistant Depression. This protocol allows eligible patients to access the i", "url": "https://www.stocktitan.net/news/NRXP/n-rx-pharmaceuticals-announces-fda-grant-of-expanded-access-protocol-2nsoc8f01idn.html", "source_name": "Stock Titan", "published_at": "2026-06-22T11:00:28", "published_display": "22 Jun 2026 11:00", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRX Pharmaceuticals Inc (NRXPW) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of NRX Pharmaceuticals Inc (NRXPW), detailing its current stock price, market capitalization, and various technical indicators. It shows that most indicators, including MACD, CCI, TRIX, and all moving averages (MA5 to MA200), are signali", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nrxpw/technical", "source_name": "TradingKey", "published_at": "2026-06-20T15:40:49", "published_display": "20 Jun 2026 15:40", "sentiment": "negative", "sentiment_pct": 15, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRXP Should I Buy", "summary": "Intellectia AI recommends a \"Hold\" rating for NRX Pharmaceuticals (NRXP) for beginner investors, citing a lack of recent financial data, neutral technical indicators, and no significant trading trends. Despite optimistic analyst ratings and potential market opportunities in the k", "url": "https://intellectia.ai/en/stock/NRXP/should-i-buy", "source_name": "Intellectia AI", "published_at": "2026-06-19T23:10:38", "published_display": "19 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals (NRXP) Closes Underwritten Public Offering of Common Stock At $3.50 Per Share", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOSllhSFJFV2JzZmJSd3Y2QXF2WXN0N0NMbEtIS0ZqempFVzNBempEM3NTZ2Q0dWVISE54NzVhbFN3MGlKZ2tmRDdiWEIxam9wS3JSUWM0Yk1zemFGQU5tUDN3WDdpbV9sQWRMdVdsUGZjakFOdzJLVXdzRVE5alRrZWoxcE9FYlVRMkZPUnQ3ZzMxaWtMNDVSVzAzdEFQcGZidDlqUVRTa1hzRTkzZTlramtFMA?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals (NASDAQ: NRXP) closes $22.3M stock sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOWmNpLTJTTHpNSjNlcHlrbkxFSldiMXpKa0dFMVFEVkpNS3RtN0RNTk1MT1U0WTlnRXZqeHRfSm9NQU9Zb1JjRmJtcU5VS20xUW1xblhtUFZFWHNfTUYwNlY3aVRrU1Jqd3BWQWRpelRFc1FHdmJFUWdHbG42QXZRYk1PZTBsUF82aU4tTTNDb0NubWIzb2ZQNndqcW0xY1NOaHNtNXg2OFV5TGtMN3B0Nll3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQaDFfOVdjMDRCakJnV010UUpWSGEwanEwNEZzSG1vOFNxSUFXZk40M0swRTNlblVOX1pCdlB3ZGF5dDBtRlBmRlhsb05BdnkzNWpMaUhqajloQTBlbWgyeFd4SERONFpTSGFTN0hfVFVudlZidmU1ZW9FcWp0ckFHenlOUE1tQ05IRmZnU2g2eURhSFk5Z3F5U3NpNzNCc0c3NXp5VHNfS3Zvdw?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is why NRx Pharmaceuticals, Inc. (NRXP) is among the Best Rated Penny Stocks to Buy According to Wall Street Analysts", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPZjVjUElteE9XQi1IajQ2Wmsyd0NQRHZKM0dOZm5BbGtReEd4djY0ZnpVN2JZcDhLc3RTTWk5UE44M2VJMHRjUlJuTlVIQjQ3WHRReDBIR3M1WnRzR2J0TndNQjY4RW1pTkI2OXQ2Z0hqZ0t6dXNVY01kX3plVlgzTm1ySjNqYzRvTkpBLTZNRTd2VUtyUEZHY2dYck9JQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-24T07:00:00+00:00", "published_display": "24 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq withdraws NRXP Warrant listing (NRXP) \u2014 Form 25 notice", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNSWl3TzhndEhLRHNpVXpJdTNqNVlxU0JTcEFkTkpQcXZtN3F4NG91SUE1Znp2dUtjYnpoeS1xb1F2RDZNR1lCWVA1WllJemNlQ1NyYi1OMFY2VFNFbEpEV0tCelpuWmw2cmx6MFlYMVhNTnJSb251WWV5VHpSZW9XQklESnpFbV83YVdzT1BZdXZKNXBkMDIwRXlhSmxwak9SdkRIS2Zn?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals: 'Sell' On ZYESAMI/NRX-101 Failures & Depression Market Uncertainty (NASDAQ:NRXP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOWFQ0Tm9wTndpclJlZnU5R3VzZGxuRFc4aXkzR1dDVDRYTVl0LUVJemdRaTRNeXlkeDdtOWdIclNNNUlySlpUUzFYazBrN19KOUd1ekdUdHVYVW9ZTko0MGdrcjZDZmptcXFram5DSTY5al94WjcwcDNzN0tGNmxFdmF4U1EwOWdaVndQUVRXcl9EWS01WXNpQUJFVWsyLXVFb2pqQk1MaVIzSE55M28ySVMtbnlvUlJjX2RrNlljeE9zTkdv?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anson Funds discloses 1.74M shares in NRX Pharmaceuticals (NRXP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPYlVRUGNweDZHdUQ2dng0VWJxLTZIOWFob0V6WnExTGpDbHFJbkJmNWJEOFY1dFBucmZSTGhiaGV4R0tuTVJCcHc4cjdHLUVidVJ2ZElxTUJ0aWJ6RWVlY09aOS0tVFNYSEdST19KVmdkdFAzSDMzdmg1WXluUmFUYk5SVTVTc2tEZnA3YzNCMERIN05hbUV3cEpFOTVtNVZFeTdoWmh2N3hudW54V2J2ZUJON2c1M0d6dEtFSlRVYW9XaVNFUHZ4VXRjOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals, Inc. (NRXP) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNeVdDOE1DaVZKbFpBak9lVC10N3p5TGx4VFNSQ0E5bGZiVE1ZZTMwR2l1Q05mQWpBZ0t1U1duSm1qSXF6SVBxa0JMeGdFaEJPd2RnUTJVbHpSczltLWZwRThsTUlKRE5ZVXBkT21RdzZmbTJsUUpBWDgzcWlTQnE2bHVpRDhVQWZJM0YyWlFzR1pMRDk2ZGJwVGEwLUx4ejFCZXZRd29CZDM?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "NRx Pharmaceuticals (NASDAQ:NRXP) Is In A Good Position To Deliver On Growth Plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQNnRaUlZlaUxjaU5iME53RXpVV2ZxczNpdmhoN29PUnJVQU55S0hWUy1ZcHE0SEcwM0ktYnFIbUhRd3JRSC1vNXJZYjBSVE1mMHlNd212akl2RUp3dDUxbnlXYm5DcThHX3kwYjNWanEtNHVYVjB2NVBhaVNaUVpFWEZoQ3A2QVBKcGtBMF80cEozTXVXS2ZVbm5ONTgwT29rSXNB?oc=5", "source_name": "Market source", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Has Found A Path To Profitability", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "NRx Pharmaceuticals (NRXP) Looks to Score Double With ANDA and NDA Filings For NRX-101", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPQ3dBSk14YURvcWRnaUNtWmREN2s2MFhjNHJKRmtkcDZLTjA5QW0zTU92WWJaS3h4X1NyMlA1R1VmMjNzM2FIMUFFYjdjNlBncmpjYlYtalQwNFdXX0FtU080MzdpRV9FMDNtOTZGLXNXbW5HZVlOVXRvVFBHUWk3ZW9MSllNOUE5VG5uSTQ2Y0l2YUhESS1yRFJqWG9kelUxN2lHYk13aXk?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals (NRXP) investors OK incentive plan and board slate", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPd2tkNVh0Vzd0akVwRW9CX3JzSGhkM2M1UFFPX3JVR0pCRGVMcWtVVFBpQzZXUG15czI3WEhkYVE1NWRCSEt5LV9mUDZrQzhaN1VSRlpEdzZRMXNvektoc1lQZW9OODBPX2plTUM0d1hyWTVHWGdSV0x6bEtXbjRPcm92TEM5YjMzUGhiYTUxZUJ0NWc1ZUVWSUdTczhNQlgwdFYyc0p2OHBxZkVnU1dlLS1n?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals, Inc. (NRXP) Surpasses Q4 Earnings Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQYm4xN1VwWW5fU20wQV9qY3FWTWQ2c0JMemNNZk85cHh0dlg4WEtuaTFDaFpfUWh4dmNJMFNURXU0Zk9vWEtxT21vQ3lkVnkteldBaFlmZVphR1hoZkduWElhc05zWWlnRzEwMXJqMzRSYjdicndJR2tXWkk4bkJmSndqOUU3ZHNmcm9GR3o2RnFPMGtWN3drZmxsOHVzSk0zMnBXY0FZdFNLNEk?oc=5", "source_name": "Market source", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx\u2019s Preservative-Free Ketamine Application", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNX0dHTEF4YWhXaXR5RXdqb2NudFRwcDNXWVlIM3RHQXc3M2hrUDlGQWNEUUxsSVFSOHRFNEtvY3BJeWlNRGg4OUk5bDhQTWhSQ1BoYWotS01iVWxLRFM3ODJIT3NrRkJ1eGcxcm9zdDI0NjdfRGZjdlhUYzJpOFlZVE80c01zYnhHdnhqSENrdkg?oc=5", "source_name": "Market source", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPMTRsYm01Q1FxYXVVSVViM0NFOVRaMkJpTjNiekdaR2hiWjU3V2R4czVoR0l3aGRoTUlsRUZ3Tk9uUWtQcjBTMGVGZm1JSlFRSUZETnpBNVN6Y2haOS1iMkVTUFkxNlFfOFBfM05qMlhlY2l1Q0J0cVYtN0dycno1WTdaOFo3bGJLbE1UZXJtMkw?oc=5", "source_name": "Market source", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgJBVV95cUxPZDcwTWhYR1NLaGdjYWRya1FDQnR3X2FTMzY2OWZGTS1Cc0VXREFUU1BTajNSc3VYLVczejBYaGR3OTBzX253TWNBa09zWGJTblZaM3N3Vlp1dGIxZW9VeUpxU20tZDZUUWo0U0RYS2JPOEI4OXlJblJhb3FRZGQ5M2tNaDExQ2xNVGhyV2JMbnVZS1Nac29NeXBOZ2tCcGI3Yi1yRl9tODhlT21HcVowbEhfTEo0WmxlZlFhS2NYTkNGZGhReWN5RXpiSXF5RlVUQ0FGQXJNNjZfdlplVC1DaVBhT0RQYS1BZlNtbl9oWGd2Yko2Rk5rOE4xMGdaMHV1SW5tUHhzOFViLXplTjJ2dVJ3ZnlScEE5MnhrUTVWQjliSGwtTXRueTk0Q2xZTUszNHY4bGJvM2p2ZnFwU1E?oc=5", "source_name": "Investing News Network", "published_at": "2025-10-20T07:00:00+00:00", "published_display": "20 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRXP|NRX Pharmaceuticals Inc|Price:4.185|Chg%:+0.075", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTE9oWTFJLUtpMVR3SVY4Qk1KNlREalYwMTVzcjRRWHRHVHdkODZra3J1QXdUUlFCUThJUElsMWR5YTQ2eXpzLW9lRXZXeTZQbGJHOW5yZzZVeHRab0dLMzFFVVhUOVBzR0h3Y3RTdGJ3?oc=5", "source_name": "TradingKey", "published_at": "2025-10-09T17:03:47+00:00", "published_display": "09 Oct 2025 17:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of Commissioner's National Priority Voucher Application for Intravenous Ketamine (NRX-100)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAJBVV95cUxOLXRodTZmMlhib040WGRuV1g2NmROUWgzT3pIR2RybERwSHotLU5jQU1jNmZhOUxIS0V5LXlBQ09UUTUyWWVlY095am55SUVpTkktTXZzcUJRS3JhRVlvS2dQSHg0MU9xcUtzelhuUlNCYTVEN0E2R0hzN2hzUXB0bC1fSU95WmhmSmk2dmw3bXZzVU4yQktCNXczNHdDUlJSaktvTWlIZWNQd0taeGNUcHhsZmduVDJRRUlKaExpMmUyMjM1dGR2ZEc0dmZOSjM3clpyQk5HRDV0NXZybjJXcHZmUHhnNldYN211X0hQWHJCZi04b0lIR3MxYzZHTTJsbkFwQmo4eE9FMzFIcUY2UXQwQjRidVZnaFF4WWFBSW4?oc=5", "source_name": "PR Newswire", "published_at": "2025-06-23T07:00:00+00:00", "published_display": "23 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals, Inc. (NRXP): Among the Best Psychedelic Stocks to Buy in 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNbnBuSlhLUElBNzNtT0xhRjlPR2ZxeWNxNkRYcWlTd0lwMmYzTExxTTZEMDFuOHJVcWZONkhFNFUtZ0tBV0ZMQXBpVmdBSzVrMG42b0ZDRkwtTjZDM2FpX3pod09NWWJ4WkxiYWdncHVNWlIxUHdSSXVkZDF3RWFNQXhpMWtmU1k?oc=5", "source_name": "Market source", "published_at": "2025-03-01T08:00:00+00:00", "published_display": "01 Mar 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Is NRx Pharmaceuticals, Inc. (NRXP) Stock Positioned for Growth Through Depression and PTSD Treatment Innovation?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPaU5kMUt0QWhmM3I1azVFWVhCbVNOZEVqbXotTHdlblJteFlxcmlkcmxHVHp2clZzdVA2SldNVzZhbklWdmVWcmV0UzVLTWRQc1Y4aXZldDJRM2tCbjJmVFFHN19WTTRTSTFnQWl3SGgxeEh0eGtMclpoTFRkbDZhZVZnMllSR1lRTklseVhvTlg0Yi1LdEtnMlMzRQ?oc=5", "source_name": "Market source", "published_at": "2026-07-15T09:21:51+00:00", "published_display": "15 Jul 2026 09:21", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Equity in earnings of NRX Pharmaceuticals, Inc. \u2013 DUS:B1Q", "summary": "This article provides financial information for NRX Pharmaceuticals, Inc. (DUS:B1Q) as listed on the Dusseldorf Stock Exchange. It specifically highlights the \"Equity in earnings\" for the company. The content appears to be a stub or a section from a larger financial data platform", "url": "https://www.tradingview.com/symbols/DUS-B1Q/financials-income-statement/equity-in-earnings/", "source_name": "TradingView", "published_at": "2026-07-09T06:12:07", "published_display": "09 Jul 2026 06:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRX Pharmaceuticals(NRXP) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAJBVV95cUxOTVlwU2p5UUpwd2cxZFh0TGhES3ZFcTd1V3hIXzk1OE9ERXBQWnVDaWVjMFZEcGx6aUxpdjJ2eHlWYno0WW9GajBXY2xQT0ZReUFIbUx4RUVmYk4wSHpVWk5ucWVDU2I2eXBJYTRxWjA0THhudUxCUkdzWWZoeXVPOVVHTEFpNER3bFBvdWdRbXNOODBqVGxpVGRzS0xEQ0tNXzNqUnUyeTFVdXBKOHN5TFZLVE5BbDY0MnhLd3NicTIwLVF5UGdiVURoN0NiY0NMd2lLYTRoOFVYNHRRdGZJYXEtampZWnU4bC03RG1FWEVGeDhZczNiRWVCVWxxWnVvaFNFZTNOVWVoSXBjVVBXQmpBazB6Tmdqd0tHSjQtOVpWVHJQbWVxajZHYTE?oc=5", "source_name": "Moomoo", "published_at": "2026-07-08T02:57:12+00:00", "published_display": "08 Jul 2026 02:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of NRX Pharmaceuticals, Inc. \u2013 NASDAQ:NRXP", "summary": "The article focuses on the enterprise value to revenue forward metric for NRX Pharmaceuticals, Inc. (NASDAQ: NRXP). It appears to be a financial data snippet from TradingView, indicating no current trades and providing an overview of where to find financial and market information", "url": "https://www.tradingview.com/symbols/NASDAQ-NRXP/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T11:09:16", "published_display": "04 Jul 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "First Patients Treated via FDA-Cleared Transcranial Magnetic Stimulation, Plus FDA Grant on D-Cycloserine-Based Drug for Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)", "summary": "NRx Pharmaceuticals, Inc. (NRXP) announced that its subsidiary, HOPE Therapeutics, has begun treating patients with the FDA-cleared Zeta TMS Navigation System for depression. Additionally, the FDA granted an Intermediate Population Expanded Access Protocol for NRX-101 (D-cycloser", "url": "https://www.barchart.com/story/news/3032983/first-patients-treated-via-fdacleared-transcranial-magnetic-stimulation-plus-fda-grant-on-dcycloserinebased-drug-for-depression-nrx-pharmaceuticals-inc-nasdaq-nrxp", "source_name": "Barchart.com", "published_at": "2026-06-30T04:40:21", "published_display": "30 Jun 2026 04:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals, Inc.(NasdaqCM:NRXP) dropped from Russell 3000E Growth Benchmark", "summary": "NRx Pharmaceuticals, Inc. (NasdaqCM: NRXP) has been removed from the Russell 3000E Growth Benchmark. The clinical-stage biopharmaceutical company focuses on developing therapeutics for central nervous system disorders, including suicidal depression, chronic pain, and PTSD. The ar", "url": "https://www.marketscreener.com/news/nrx-pharmaceuticals-inc-nasdaqcm-nrxp-dropped-from-russell-3000e-growth-benchmark-ce7f5fdeda81f42d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:41:44", "published_display": "29 Jun 2026 05:41", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals, Inc.(NasdaqCM:NRXP) dropped from Russell Microcap Growth Benchmark Index", "summary": "NRx Pharmaceuticals, Inc. (NasdaqCM:NRXP) has been removed from the Russell Microcap Growth Benchmark Index. This follows a previous announcement on June 29th that the company was also dropped from the Russell 3000E Growth Benchmark. NRx Pharmaceuticals is a clinical-stage biopha", "url": "https://www.marketscreener.com/news/nrx-pharmaceuticals-inc-nasdaqcm-nrxp-dropped-from-russell-microcap-growth-benchmark-index-ce7f5fdcd88fff23", "source_name": "marketscreener.com", "published_at": "2026-06-29T03:39:09", "published_display": "29 Jun 2026 03:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of NRX Pharmaceuticals, Inc. \u2013 DUS:B1Q", "summary": "The article focuses on the enterprise value to revenue forward metric for NRX Pharmaceuticals, Inc. (DUS:B1Q), traded on the Dusseldorf Stock Exchange. It highlights financial data and market information related to the company's valuation. The content appears to be a stub or a se", "url": "https://www.tradingview.com/symbols/DUS-B1Q/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T16:10:38", "published_display": "28 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition", "summary": "Kadima Neuropsychiatry Institute and its founder, Dr. David Feifel, have filed a lawsuit against NRx Pharmaceuticals (NASDAQ: NRXP) and its subsidiaries, alleging breach of contract and misrepresentation regarding an acquisition agreement. The suit claims NRx warranted it had suf", "url": "https://finance.yahoo.com/markets/stocks/articles/kadima-neuropsychiatry-institute-files-suit-171800479.html", "source_name": "Market source", "published_at": "2026-06-28T05:09:48", "published_display": "28 Jun 2026 05:09", "sentiment": "negative", "sentiment_pct": 14, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of NRX Pharmaceuticals, Inc. \u2013 DUS:B1Q", "summary": "The article displays the \"Price to book forward\" for NRX Pharmaceuticals, Inc. (DUS:B1Q) on the Dusseldorf Stock Exchange according to TradingView. It indicates that the market is currently closed with no trades. The core content is limited to this financial metric and general ma", "url": "https://www.tradingview.com/symbols/DUS-B1Q/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T00:10:17", "published_display": "28 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of NRX Pharmaceuticals, Inc. \u2013 NASDAQ:NRXP", "summary": "This article provides a brief snapshot of the \"Price to sales forward\" metric for NRX Pharmaceuticals, Inc. (NASDAQ: NRXP) as listed on TradingView. It indicates that no specific value or change information is currently displayed, suggesting the data may be unavailable or pending", "url": "https://www.tradingview.com/symbols/NASDAQ-NRXP/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T00:10:17", "published_display": "28 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of NRX Pharmaceuticals, Inc. \u2013 DUS:B1Q", "summary": "This article provides financial information for NRX Pharmaceuticals, Inc. (B1Q) on the Dusseldorf Stock Exchange. It specifically highlights the \"Price to sales forward\" metric for the company. The content appears to be a stub or a data point from a financial platform, indicating", "url": "https://www.tradingview.com/symbols/DUS-B1Q/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T23:39:10", "published_display": "27 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System", "summary": "NRx Pharmaceuticals' subsidiary, HOPE Therapeutics, has started treating patients using Zeta Surgical's FDA-cleared Zeta TMS Navigation System at its clinics in Florida. This system employs AI-powered, sub-millimetric image guidance for Transcranial Magnetic Stimulation (TMS) pro", "url": "https://finance.yahoo.com/healthcare/articles/nrx-pharmaceuticals-nasdaq-nrxp-subsidiary-110000556.html", "source_name": "Market source", "published_at": "2026-06-27T19:10:06", "published_display": "27 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression", "summary": "NRx Pharmaceuticals announced that the FDA has granted an Intermediate Population Expanded Access Protocol for NRX-101, a D-cycloserine-based drug, to augment Transcranial Magnetic Stimulation (TMS) in patients with treatment-resistant depression. This protocol allows access to N", "url": "https://finance.yahoo.com/healthcare/articles/nrx-pharmaceuticals-announces-fda-grant-110000219.html", "source_name": "Market source", "published_at": "2026-06-26T16:39:35", "published_display": "26 Jun 2026 16:39", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Keeps Their Buy Rating on NRX Pharmaceuticals (NRXP)", "summary": "H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on NRX Pharmaceuticals (NRXP) with a $45.00 price target, highlighting his strong track record in the Healthcare sector. The analyst consensus for NRX Pharmaceuticals remains a Strong Buy with an average price targe", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/16051/h-c-wainwright-keeps-their-buy-rating-on-nrx-pharmaceuticals-nrxp/", "source_name": "The Globe and Mail", "published_at": "2026-06-26T12:49:31", "published_display": "26 Jun 2026 12:49", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRX Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:NRXP)", "summary": "This article provides an overview of NRX Pharmaceuticals, Inc. (NASDAQ: NRXP) stock performance, financial actuals, and analyst estimates. It covers the current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings reports, along with an", "url": "https://www.tradingview.com/symbols/NASDAQ-NRXP/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T04:39:23", "published_display": "26 Jun 2026 04:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute", "summary": "NRx Pharmaceuticals (NRXP) issued a statement addressing \"unfounded allegations\" made by Kadima Neuropsychiatry Institute concerning the non-acquisition of Kadima by HOPE Therapeutics, an NRx subsidiary. NRx stated that it has compelled arbitration due to Kadima's failure to meet", "url": "https://www.globenewswire.com/news-release/2026/06/25/3317921/0/en/nrx-pharmaceuticals-responds-to-recent-public-statements-regarding-kadima-dispute.html", "source_name": "GlobeNewswire", "published_at": "2026-06-25T20:09:57", "published_display": "25 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System", "summary": "HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, has begun treating patients using Zeta Surgical's FDA-cleared Zeta TMS Navigation System at its clinics in West Palm Beach and Sarasota, Florida. This marks the transition from research deployment to active patient care, inc", "url": "https://investingnews.com/nrx-pharmaceuticals-subsidiary-hope-therapeutics-treats-first-patients-using-zeta-surgical-s-fda-cleared-zeta-tms-navigation-system/", "source_name": "Investing News Network", "published_at": "2026-06-25T14:09:57", "published_display": "25 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HOPE starts first FDA-cleared TMS treatments in Florida clinics", "summary": "NRx Pharmaceuticals' subsidiary, HOPE Therapeutics, has begun treating patients with Zeta Surgical's FDA-cleared Zeta TMS Navigation System in West Palm Beach and Sarasota, Florida. This system provides AI-guided, sub-millimetric image guidance for Transcranial Magnetic Stimulati", "url": "https://www.stocktitan.net/news/NRXP/n-rx-pharmaceuticals-nasdaq-nrxp-subsidiary-hope-therapeutics-treats-imxuappq0nn1.html", "source_name": "Stock Titan", "published_at": "2026-06-25T10:41:06", "published_display": "25 Jun 2026 10:41", "sentiment": "positive", "sentiment_pct": 76, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kadima Neuropsychiatry Institute Sues NRX Pharmaceuticals Over Breach of Acquisition Contract", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/kadima-neuropsychiatry-institute-sues-nrx-184440397.html", "source_name": "MT Newswires", "published_at": "2026-06-24T18:44:40+00:00", "published_display": "24 Jun 2026 18:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kadima sues NRx Pharmaceuticals over failed acquisition deal", "summary": "Kadima Neuropsychiatry Institute has filed a lawsuit against NRx Pharmaceuticals and its subsidiaries, alleging breach of contract and misrepresentation regarding a failed acquisition deal. Kadima claims NRx announced the acquisition and saw a significant stock surge, but then in", "url": "https://m.uk.investing.com/news/stock-market-news/kadima-sues-nrx-pharmaceuticals-over-failed-acquisition-deal-93CH-4742937?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-24T18:39:42", "published_display": "24 Jun 2026 18:39", "sentiment": "negative", "sentiment_pct": 13, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EBIT per share of NRX Pharmaceuticals, Inc. \u2013 DUS:B1Q", "summary": "The article provides the EBIT (Earnings Before Interest and Taxes) per share for NRX Pharmaceuticals, Inc., traded on the Dusseldorf Stock Exchange under the symbol B1Q. It indicates that the market is closed with no recent trades. The content is presented as a financial data poi", "url": "https://www.tradingview.com/symbols/DUS-B1Q/financials-statistics-and-ratios/ebit-per-share/", "source_name": "TradingView", "published_at": "2026-06-24T13:39:49", "published_display": "24 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cash per share of NRX Pharmaceuticals, Inc. \u2013 DUS:B1Q", "summary": "The article focuses on the \"Cash per share\" financial metric for NRX Pharmaceuticals, Inc. (DUS:B1Q) listed on the Dusseldorf Stock Exchange. It appears to be a financial data page from TradingView, indicating the company's financial overview, specifically its cash per share valu", "url": "https://www.tradingview.com/symbols/DUS-B1Q/financials-statistics-and-ratios/cash-per-share/", "source_name": "TradingView", "published_at": "2026-06-24T13:10:31", "published_display": "24 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tangible book value per share of NRX Pharmaceuticals, Inc. \u2013 DUS:B1Q", "summary": "This article provides financial data for NRX Pharmaceuticals, Inc. (DUS:B1Q) from TradingView, specifically focusing on its tangible book value per share. The content indicates the market status as closed with no recent trades for the stock on the Dusseldorf Stock Exchange. It hi", "url": "https://www.tradingview.com/symbols/DUS-B1Q/financials-statistics-and-ratios/book-tangible-per-share/", "source_name": "TradingView", "published_at": "2026-06-23T22:12:51", "published_display": "23 Jun 2026 22:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRX Pharmaceuticals' Hope Therapeutics, Zeta Surgical Treat First Patient With Zeta TMS Navigation System", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/nrx-pharmaceuticals-apos-hope-therapeutics-162121693.html", "source_name": "MT Newswires", "published_at": "2026-06-23T16:21:21+00:00", "published_display": "23 Jun 2026 16:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals gets FDA approval for NRX-101 protocol", "summary": "NRx Pharmaceuticals (NASDAQ:NRXP) has received FDA authorization for an expanded access program for its depression treatment drug candidate, NRX-101. This compassionate care decision allows the medication to be obtained by physicians with patients only covering shipping and data ", "url": "https://grafa.com/en/news/united-states/nrx-pharmaceuticals-nrxp-fda-approval-nrx-101-depression-2026", "source_name": "grafa.com", "published_at": "2026-06-22T13:46:00", "published_display": "22 Jun 2026 13:46", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals Receives Expanded Access Approval for Experimental Depression Treatment", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/nrx-pharmaceuticals-receives-expanded-access-115612841.html", "source_name": "MT Newswires", "published_at": "2026-06-22T11:56:12+00:00", "published_display": "22 Jun 2026 11:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals Announces FDA Grant of Expanded Access", "summary": "NRx Pharmaceuticals announced that the FDA has granted an Intermediate Population Expanded Access Protocol for NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. This protocol allows the investigational drug to be used in conjunction with Transcranial Magnet", "url": "https://www.globenewswire.com/news-release/2026/06/22/3315163/0/en/nrx-pharmaceuticals-announces-fda-grant-of-expanded-access-protocol-for-use-of-d-cycloserine-based-nrx-101-for-augmentation-of-transcranial-magnetic-stimulation-in-the-treatment-of.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T11:00:28", "published_display": "22 Jun 2026 11:00", "sentiment": "positive", "sentiment_pct": 94, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA lets NRx offer NRX-101 with TMS for severe depression", "summary": "NRx Pharmaceuticals announced that the FDA has authorized an Intermediate Population Expanded Access Protocol for NRX-101 to be used with accelerated Transcranial Magnetic Stimulation (TMS) for Treatment-Resistant Depression. This protocol allows eligible patients to access the i", "url": "https://www.stocktitan.net/news/NRXP/n-rx-pharmaceuticals-announces-fda-grant-of-expanded-access-protocol-2nsoc8f01idn.html", "source_name": "Stock Titan", "published_at": "2026-06-22T11:00:28", "published_display": "22 Jun 2026 11:00", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRX Pharmaceuticals Inc (NRXPW) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of NRX Pharmaceuticals Inc (NRXPW), detailing its current stock price, market capitalization, and various technical indicators. It shows that most indicators, including MACD, CCI, TRIX, and all moving averages (MA5 to MA200), are signali", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nrxpw/technical", "source_name": "TradingKey", "published_at": "2026-06-20T15:40:49", "published_display": "20 Jun 2026 15:40", "sentiment": "negative", "sentiment_pct": 15, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRXP Should I Buy", "summary": "Intellectia AI recommends a \"Hold\" rating for NRX Pharmaceuticals (NRXP) for beginner investors, citing a lack of recent financial data, neutral technical indicators, and no significant trading trends. Despite optimistic analyst ratings and potential market opportunities in the k", "url": "https://intellectia.ai/en/stock/NRXP/should-i-buy", "source_name": "Intellectia AI", "published_at": "2026-06-19T23:10:38", "published_display": "19 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals (NRXP) Closes Underwritten Public Offering of Common Stock At $3.50 Per Share", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOSllhSFJFV2JzZmJSd3Y2QXF2WXN0N0NMbEtIS0ZqempFVzNBempEM3NTZ2Q0dWVISE54NzVhbFN3MGlKZ2tmRDdiWEIxam9wS3JSUWM0Yk1zemFGQU5tUDN3WDdpbV9sQWRMdVdsUGZjakFOdzJLVXdzRVE5alRrZWoxcE9FYlVRMkZPUnQ3ZzMxaWtMNDVSVzAzdEFQcGZidDlqUVRTa1hzRTkzZTlramtFMA?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals (NASDAQ: NRXP) closes $22.3M stock sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOWmNpLTJTTHpNSjNlcHlrbkxFSldiMXpKa0dFMVFEVkpNS3RtN0RNTk1MT1U0WTlnRXZqeHRfSm9NQU9Zb1JjRmJtcU5VS20xUW1xblhtUFZFWHNfTUYwNlY3aVRrU1Jqd3BWQWRpelRFc1FHdmJFUWdHbG42QXZRYk1PZTBsUF82aU4tTTNDb0NubWIzb2ZQNndqcW0xY1NOaHNtNXg2OFV5TGtMN3B0Nll3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQaDFfOVdjMDRCakJnV010UUpWSGEwanEwNEZzSG1vOFNxSUFXZk40M0swRTNlblVOX1pCdlB3ZGF5dDBtRlBmRlhsb05BdnkzNWpMaUhqajloQTBlbWgyeFd4SERONFpTSGFTN0hfVFVudlZidmU1ZW9FcWp0ckFHenlOUE1tQ05IRmZnU2g2eURhSFk5Z3F5U3NpNzNCc0c3NXp5VHNfS3Zvdw?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is why NRx Pharmaceuticals, Inc. (NRXP) is among the Best Rated Penny Stocks to Buy According to Wall Street Analysts", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPZjVjUElteE9XQi1IajQ2Wmsyd0NQRHZKM0dOZm5BbGtReEd4djY0ZnpVN2JZcDhLc3RTTWk5UE44M2VJMHRjUlJuTlVIQjQ3WHRReDBIR3M1WnRzR2J0TndNQjY4RW1pTkI2OXQ2Z0hqZ0t6dXNVY01kX3plVlgzTm1ySjNqYzRvTkpBLTZNRTd2VUtyUEZHY2dYck9JQQ?oc=5", "source_name": "Market source", "published_at": "2026-05-24T07:00:00+00:00", "published_display": "24 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq withdraws NRXP Warrant listing (NRXP) \u2014 Form 25 notice", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNSWl3TzhndEhLRHNpVXpJdTNqNVlxU0JTcEFkTkpQcXZtN3F4NG91SUE1Znp2dUtjYnpoeS1xb1F2RDZNR1lCWVA1WllJemNlQ1NyYi1OMFY2VFNFbEpEV0tCelpuWmw2cmx6MFlYMVhNTnJSb251WWV5VHpSZW9XQklESnpFbV83YVdzT1BZdXZKNXBkMDIwRXlhSmxwak9SdkRIS2Zn?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals: 'Sell' On ZYESAMI/NRX-101 Failures & Depression Market Uncertainty (NASDAQ:NRXP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOWFQ0Tm9wTndpclJlZnU5R3VzZGxuRFc4aXkzR1dDVDRYTVl0LUVJemdRaTRNeXlkeDdtOWdIclNNNUlySlpUUzFYazBrN19KOUd1ekdUdHVYVW9ZTko0MGdrcjZDZmptcXFram5DSTY5al94WjcwcDNzN0tGNmxFdmF4U1EwOWdaVndQUVRXcl9EWS01WXNpQUJFVWsyLXVFb2pqQk1MaVIzSE55M28ySVMtbnlvUlJjX2RrNlljeE9zTkdv?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Anson Funds discloses 1.74M shares in NRX Pharmaceuticals (NRXP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPYlVRUGNweDZHdUQ2dng0VWJxLTZIOWFob0V6WnExTGpDbHFJbkJmNWJEOFY1dFBucmZSTGhiaGV4R0tuTVJCcHc4cjdHLUVidVJ2ZElxTUJ0aWJ6RWVlY09aOS0tVFNYSEdST19KVmdkdFAzSDMzdmg1WXluUmFUYk5SVTVTc2tEZnA3YzNCMERIN05hbUV3cEpFOTVtNVZFeTdoWmh2N3hudW54V2J2ZUJON2c1M0d6dEtFSlRVYW9XaVNFUHZ4VXRjOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals, Inc. (NRXP) Reports Q1 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNeVdDOE1DaVZKbFpBak9lVC10N3p5TGx4VFNSQ0E5bGZiVE1ZZTMwR2l1Q05mQWpBZ0t1U1duSm1qSXF6SVBxa0JMeGdFaEJPd2RnUTJVbHpSczltLWZwRThsTUlKRE5ZVXBkT21RdzZmbTJsUUpBWDgzcWlTQnE2bHVpRDhVQWZJM0YyWlFzR1pMRDk2ZGJwVGEwLUx4ejFCZXZRd29CZDM?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals (NASDAQ:NRXP) Is In A Good Position To Deliver On Growth Plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQNnRaUlZlaUxjaU5iME53RXpVV2ZxczNpdmhoN29PUnJVQU55S0hWUy1ZcHE0SEcwM0ktYnFIbUhRd3JRSC1vNXJZYjBSVE1mMHlNd212akl2RUp3dDUxbnlXYm5DcThHX3kwYjNWanEtNHVYVjB2NVBhaVNaUVpFWEZoQ3A2QVBKcGtBMF80cEozTXVXS2ZVbm5ONTgwT29rSXNB?oc=5", "source_name": "Market source", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Has Found A Path To Profitability", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals (NRXP) Looks to Score Double With ANDA and NDA Filings For NRX-101", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPQ3dBSk14YURvcWRnaUNtWmREN2s2MFhjNHJKRmtkcDZLTjA5QW0zTU92WWJaS3h4X1NyMlA1R1VmMjNzM2FIMUFFYjdjNlBncmpjYlYtalQwNFdXX0FtU080MzdpRV9FMDNtOTZGLXNXbW5HZVlOVXRvVFBHUWk3ZW9MSllNOUE5VG5uSTQ2Y0l2YUhESS1yRFJqWG9kelUxN2lHYk13aXk?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals (NRXP) investors OK incentive plan and board slate", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPd2tkNVh0Vzd0akVwRW9CX3JzSGhkM2M1UFFPX3JVR0pCRGVMcWtVVFBpQzZXUG15czI3WEhkYVE1NWRCSEt5LV9mUDZrQzhaN1VSRlpEdzZRMXNvektoc1lQZW9OODBPX2plTUM0d1hyWTVHWGdSV0x6bEtXbjRPcm92TEM5YjMzUGhiYTUxZUJ0NWc1ZUVWSUdTczhNQlgwdFYyc0p2OHBxZkVnU1dlLS1n?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals, Inc. (NRXP) Surpasses Q4 Earnings Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQYm4xN1VwWW5fU20wQV9qY3FWTWQ2c0JMemNNZk85cHh0dlg4WEtuaTFDaFpfUWh4dmNJMFNURXU0Zk9vWEtxT21vQ3lkVnkteldBaFlmZVphR1hoZkduWElhc05zWWlnRzEwMXJqMzRSYjdicndJR2tXWkk4bkJmSndqOUU3ZHNmcm9GR3o2RnFPMGtWN3drZmxsOHVzSk0zMnBXY0FZdFNLNEk?oc=5", "source_name": "Market source", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx\u2019s Preservative-Free Ketamine Application", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxNX0dHTEF4YWhXaXR5RXdqb2NudFRwcDNXWVlIM3RHQXc3M2hrUDlGQWNEUUxsSVFSOHRFNEtvY3BJeWlNRGg4OUk5bDhQTWhSQ1BoYWotS01iVWxLRFM3ODJIT3NrRkJ1eGcxcm9zdDI0NjdfRGZjdlhUYzJpOFlZVE80c01zYnhHdnhqSENrdkg?oc=5", "source_name": "Market source", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPMTRsYm01Q1FxYXVVSVViM0NFOVRaMkJpTjNiekdaR2hiWjU3V2R4czVoR0l3aGRoTUlsRUZ3Tk9uUWtQcjBTMGVGZm1JSlFRSUZETnpBNVN6Y2haOS1iMkVTUFkxNlFfOFBfM05qMlhlY2l1Q0J0cVYtN0dycno1WTdaOFo3bGJLbE1UZXJtMkw?oc=5", "source_name": "Market source", "published_at": "2026-01-14T08:00:00+00:00", "published_display": "14 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgJBVV95cUxPZDcwTWhYR1NLaGdjYWRya1FDQnR3X2FTMzY2OWZGTS1Cc0VXREFUU1BTajNSc3VYLVczejBYaGR3OTBzX253TWNBa09zWGJTblZaM3N3Vlp1dGIxZW9VeUpxU20tZDZUUWo0U0RYS2JPOEI4OXlJblJhb3FRZGQ5M2tNaDExQ2xNVGhyV2JMbnVZS1Nac29NeXBOZ2tCcGI3Yi1yRl9tODhlT21HcVowbEhfTEo0WmxlZlFhS2NYTkNGZGhReWN5RXpiSXF5RlVUQ0FGQXJNNjZfdlplVC1DaVBhT0RQYS1BZlNtbl9oWGd2Yko2Rk5rOE4xMGdaMHV1SW5tUHhzOFViLXplTjJ2dVJ3ZnlScEE5MnhrUTVWQjliSGwtTXRueTk0Q2xZTUszNHY4bGJvM2p2ZnFwU1E?oc=5", "source_name": "Investing News Network", "published_at": "2025-10-20T07:00:00+00:00", "published_display": "20 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRXP|NRX Pharmaceuticals Inc|Price:4.185|Chg%:+0.075", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTE9oWTFJLUtpMVR3SVY4Qk1KNlREalYwMTVzcjRRWHRHVHdkODZra3J1QXdUUlFCUThJUElsMWR5YTQ2eXpzLW9lRXZXeTZQbGJHOW5yZzZVeHRab0dLMzFFVVhUOVBzR0h3Y3RTdGJ3?oc=5", "source_name": "TradingKey", "published_at": "2025-10-09T17:03:47+00:00", "published_display": "09 Oct 2025 17:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of Commissioner's National Priority Voucher Application for Intravenous Ketamine (NRX-100)", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAJBVV95cUxOLXRodTZmMlhib040WGRuV1g2NmROUWgzT3pIR2RybERwSHotLU5jQU1jNmZhOUxIS0V5LXlBQ09UUTUyWWVlY095am55SUVpTkktTXZzcUJRS3JhRVlvS2dQSHg0MU9xcUtzelhuUlNCYTVEN0E2R0hzN2hzUXB0bC1fSU95WmhmSmk2dmw3bXZzVU4yQktCNXczNHdDUlJSaktvTWlIZWNQd0taeGNUcHhsZmduVDJRRUlKaExpMmUyMjM1dGR2ZEc0dmZOSjM3clpyQk5HRDV0NXZybjJXcHZmUHhnNldYN211X0hQWHJCZi04b0lIR3MxYzZHTTJsbkFwQmo4eE9FMzFIcUY2UXQwQjRidVZnaFF4WWFBSW4?oc=5", "source_name": "PR Newswire", "published_at": "2025-06-23T07:00:00+00:00", "published_display": "23 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NRx Pharmaceuticals, Inc. (NRXP): Among the Best Psychedelic Stocks to Buy in 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxNbnBuSlhLUElBNzNtT0xhRjlPR2ZxeWNxNkRYcWlTd0lwMmYzTExxTTZEMDFuOHJVcWZONkhFNFUtZ0tBV0ZMQXBpVmdBSzVrMG42b0ZDRkwtTjZDM2FpX3pod09NWWJ4WkxiYWdncHVNWlIxUHdSSXVkZDF3RWFNQXhpMWtmU1k?oc=5", "source_name": "Market source", "published_at": "2025-03-01T08:00:00+00:00", "published_display": "01 Mar 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 101, "total_relevant": 58, "sentiment_summary": {"positive": 14, "negative": 9, "neutral": 35, "score": 52, "total": 58, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 16.85, "count": 30}, {"event": "earnings", "label": "Earnings", "weight": 7.15, "count": 15}, {"event": "deals", "label": "Deals and strategy", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.2, "count": 4}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}], "positive_events": 14, "negative_events": 9}, "market_context": {"has_market_context": true, "latest_close": 4.19, "latest_week": "2026-07-10", "one_week_move": 8.3, "four_week_move": 9.1, "twelve_week_move": 64.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.888468, "market_dynamics_buy_signal": false, "relative_strength": 32.640039, "fair_value_gap": 46.9, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 36.1569, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+8.3% over one week, +9.1% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 60, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 19}, {"label": "TradingView", "count": 11}, {"label": "Stock Titan", "count": 6}, {"label": "MT Newswires", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "GlobeNewswire", "count": 2}, {"label": "Investing News Network", "count": 2}, {"label": "TradingKey", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 50}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Earnings", "count": 15}, {"label": "Deals and strategy", "count": 4}, {"label": "Regulatory and legal", "count": 4}, {"label": "Guidance", "count": 2}, {"label": "Analyst action", "count": 2}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "50", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+8.3% over one week, +9.1% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Is NRx Pharmaceuticals, Inc. (NRXP) Stock Positioned for Growth Through Depression and PTSD Treatment Innovation?"}], "updated_at": "2026-07-16T08:06:31.820027+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}